See Supplemental Patient Information
- Use chlorthalidone with caution in severe renal impairment, as it may increase the risk of azotemia
- Use chlorthalidone with caution in hepatic disease or progressive renal disease as minor alterations in electrolyte and fluid balance can precipitate hepatic coma
- Hypersensitivity may occur in patients with or without history of allergy or bronchial asthma
- Dose-related hypokalemia, hyponatremia and hyperchloremic alkalosis are observed in patients receiving chlorthalidone. Hence determine serum electrolytes before initiating therapy and at periodic intervals
- Monitor for signs of fluid or electrolyte imbalance viz dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, palpitations and gastrointestinal disturbances, like nausea and vomiting
- Reduce dose of clonidine over 2-4 days to avoid withdrawal symptoms. Sudden cessation has resulted in nervousness, agitation, headache, and tremor, accompanied or followed by a rapid rise in blood pressure. Rare cases of hypertensive encephalopathy and death have been reported
- Increased risk of withdrawal symptoms is observed if concomitant beta blocker therapy is administered, hence beta-blockers should be discontinued several days before the gradual withdrawal of clonidine hydrochloride
- In perioperative use continue clonidine therapy within 4 hrs of surgery and resume after as soon as possible
- Patients who develop an allergic reaction from clonidine transdermal system may also elicit allergic reactions (eg, generalized skin rash, urticaria, angioedema)
Cautions: Use cautiously in
- Concomitant lithium use
- Severe renal disease
- Chronic renal failure
- Hepatic impairment
- Progressive liver disease
- Severe coronary insufficiency
- Recent myocardial infarction
- Cerebrovascular disease
- Electrolyte abnormalities
- Volume depletion
- Seizure disorder
- Arrhythmias
- Diabetes mellitus
- Systemic lupus erythematosus
- History of gout
- History of pancreatitis
- Near-term pregnancy
- Gestational HTN
- Elderly
Supplemental Patient Information
- Warn patients against discontinuation of clonidine therapy without consulting their physician
- Advise patients who are engaged in potentially hazardous activities, such as operating machinery or driving, about the potential sedative effect of clonidine
Pregnancy Category:C
Breastfeeding: Chlorthalidone excreted in breast milk in small amount, however due to its slow clearance accumulation may occur in the infant especially while nursing a newborn or preterm infant. It may also suppress lactation, alternate drugs may be preffered. High levels of clonidine found in breastfed infants and also due to its possible negative effects on lactation, other agents may be preferred. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 October 2013). According to the manufacturer data, use cautiously in nursing woman as clonidine is excreted in human milk
US Trade Name(s)
US Availability
Clorpres (chlorthalidone/clonidine)
- TABS: 15 mg/0.1 mg
- TABS: 15 mg/0.2 mg
- TABS: 15 mg/0.3 mg
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
Pricing data from www.DrugStore.com in U.S.A.
- Clorpres 0.1-15 MG TABS [Bottle] (MYLAN)
60 mg = $127.99
180 mg = $358.57 - Clorpres 0.2-15 MG TABS [Bottle] (MYLAN BERTEK)
60 mg = $115.99
180 mg = $315.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.